<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878055</url>
  </required_header>
  <id_info>
    <org_study_id>REP0220</org_study_id>
    <secondary_id>2020-005919-51</secondary_id>
    <nct_id>NCT04878055</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.</brief_title>
  <official_title>A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to assess Efficacy and safety of Reparixin treatment as compared to&#xD;
      placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 clinical trial designed as a randomized, double-blind, placebo-controlled,&#xD;
      multicentre study to evaluate the efficacy and safety of Reparixin in hospitalized adult&#xD;
      patients with severe COVID-19 pneumonia.&#xD;
&#xD;
      Patients will be screened for the participation in the study and eventually randomized based&#xD;
      on an unbalanced randomization scheme (2:1) to Reparixin oral tablets (2 x 600 mg TID) for up&#xD;
      to 21 days or to placebo.&#xD;
&#xD;
      An unequal randomization is justified by the need to gain experience and more safety data&#xD;
      with the investigated treatment and by an expected better acceptability of the trial by&#xD;
      patients.&#xD;
&#xD;
      The placebo control arm is justified by the unavailability of a well-defined standard of care&#xD;
      for subjects with COVID-19 pneumonia who are candidates for this study.&#xD;
&#xD;
      All patient will receive the standard supportive care based on the patient's clinical need.&#xD;
      Follow-up information on the patient's clinical condition will be collected until day 90.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>subjects will be randomized with a 2:1 randomization ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive and free of respiratory failure at Day 28</measure>
    <time_frame>At day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and free of respiratory failure at day 60</measure>
    <time_frame>At day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates up to Day 28</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICU admission until Day 28</measure>
    <time_frame>Until day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery (category 1 - 2 - 3 of the 7-point WHO Ordinal Scale of clinical improvement (WHO-OS)) until Day 28</measure>
    <time_frame>Until Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and free of respiratory failure at fixed time-points</measure>
    <time_frame>At Days 3, 7(±1),14(±2), 21(±2), 28 (±2), 60(±2) after randomization (randomization = day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From randomization till the last follow-up, up to 90 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Reparixin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reparixin</intervention_name>
    <description>2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).</description>
    <arm_group_label>Reparixin</arm_group_label>
    <other_name>DF 1681Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 90, male and female subject of any race&#xD;
&#xD;
          2. Reverse transcriptase Polymerase Chain Reaction (rt-PCR)-confirmed COVID-19 infection&#xD;
             based on a nasal / oropharyngeal swab within 10 days before randomization&#xD;
&#xD;
          3. At least one of the following: 1) Respiratory distress with tachypnea (RR ≥ 24&#xD;
             breaths/min without oxygen); 2) Partial arterial oxygen pressure (PaO2) / Fraction of&#xD;
             inspiration O2 (FiO2), P/F &gt;100 and &lt;300 mmHg (1mmHg = 0.133kPa), 3) SpO2 ≤ 94% while&#xD;
             breathing ambient air.&#xD;
&#xD;
             Calculation through validated Sat/FiO2 scales is allowed. P/F value of reference if&#xD;
             the last available before the signature of consent.&#xD;
&#xD;
          4. Need of supplemental oxygen (i.e. new use of supplemental oxygen, or increased oxygen&#xD;
             requirement if on chronic oxygen) requiring low- or high-flow oxygen or non-invasive&#xD;
             mechanical ventilation (7-point WHO-OS category 4 or 5).&#xD;
&#xD;
          5. Radiological chest imaging (X-rays, CT scan) confirms lung involvement and&#xD;
             inflammation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cannot obtain informed consent.&#xD;
&#xD;
          2. Hepatic dysfunction with Child Pugh score B or C, or ALT or AST&gt; 5 times the upper&#xD;
             limit.&#xD;
&#xD;
          3. Renal dysfunction with estimated glomerular filtration rate (MDRD) &lt; 50 mL/min/1.73 m2&#xD;
             or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal&#xD;
             dialysis.&#xD;
&#xD;
          4. Bacterial sepsis (besides COVID-19 sepsis).&#xD;
&#xD;
          5. Known congenital or acquired immune deficiency.&#xD;
&#xD;
          6. Positive or missing pregnancy test before first drug intake or day 1; pregnant or&#xD;
             lactating women; women of childbearing potential and fertile men who do not agree to&#xD;
             use at least one primary form of contraception for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Landoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale San Raffaele Centro di Ricerca Anestesia e Rianimazione</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria De Pizzol, BSc, PhD</last_name>
    <phone>+39 02 583831</phone>
    <email>clinops@pec.dompe.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanna Di Turi, BSc</last_name>
    <phone>+39 02 583831</phone>
    <email>clinops@pec.dompe.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Washington University Medical Faculty Associates, 2150 Pennsylvania Avenue NW</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wald, PA-C, MS</last_name>
      <email>jwald@mfa.gwu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscan Alliance, 421 N Emerson Ave,</name>
      <address>
        <city>Greenwood</city>
        <state>Indiana</state>
        <zip>46143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Kioussopoulos, MBA</last_name>
      <email>Kathleen.Kioussopoulos@franciscanalliance.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi UO di Pneumologia e Terapia Int. Respiratoria</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Nava, MD</last_name>
      <email>stefanava@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino Malattie infettive e tropicali</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Bassetti, MD</last_name>
      <email>matteo.bassetti@hsanmartino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale regionale San Salvatore U.O.C. Anestesia e Rianimazione</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Marinangeli, Prof, MD</last_name>
      <email>franco.marinangeli@univaq.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas U.O. Medicina D'Urgenza</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Voza, MD</last_name>
      <email>antonio.voza@humanitas.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda Dipartimento Malattie Infettive</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Puoti, MD</last_name>
      <email>massimo.puoti@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele Centro di Ricerca Anestesia e Rianimazione</name>
      <address>
        <city>MIlan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Landoni, Prof, MD</last_name>
      <email>landoni.giovanni@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST SANTI PAOLO E CARLO Ospedale San Paolo Struttura Complessa Malattie Infettive</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Darminio, Prof, MD</last_name>
      <email>antonella.darminio@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST-Monza Ospedale San Gerardo Malattie Infettive</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Bonfanti, MD</last_name>
      <email>p.bonfanti@asst-monza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Federico II Malattie Infettive del Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Gentile, MD</last_name>
      <email>ivan.gentile@unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università della Campania &quot;Luigi Vanvitelli&quot; Dipartimento di Malattie Infettive</name>
      <address>
        <city>Napoli</city>
        <zip>80133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Coppola, MD</last_name>
      <email>nicola.coppola@unicampania.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico UOC Anestesia e Rianimazione</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Mattei, MD</last_name>
      <email>a.mattei@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico Umberto I, UOC Malattie Infettive</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Maria Mastroianni, MD</last_name>
      <email>claudio.mastroianni@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico Universitario &quot;Agostino Gemelli&quot; - Istituto di Clinica delle Malattie Infettive</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Cauda, MD</last_name>
      <email>roberto.cauda@unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST dei Sette Laghi Ospedale di Circolo e Fondazione Macchi Struttura Complessa Malattie infettive e tropicali</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Grossi, Prof, MD</last_name>
      <email>paolo.grossi@uninsubria.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Integrata di Verona U.O. Medicina Respiratoria, sezione di Medicina Interna</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Crisafulli, Prof., MD</last_name>
      <email>ernesto.crisafulli@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Severe pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

